Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis.
Purpose: The aim of this study was to describe the efficacy and safety of anti–interleukin 6 receptor antibody (tocilizumab [TCZ]) in patients with severe or refractory Takayasu arteritis (TA). Methods: We describe 8 Colombian patients with severe and/or refractory TA treated with TCZ during a perio...
| Autor: | |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2014 |
| País: | Colombia |
| Institución: | Universidad ICESI |
| Repositorio: | Repositorio ICESI |
| Idioma: | inglés |
| OAI Identifier: | oai:repository.icesi.edu.co:10906/78520 |
| Acceso en línea: | http://journals.lww.com/jclinrheum/Abstract/2014/04000/Efficacy_and_Safety_of_Anti_Interleukin_6_Receptor.2.aspx http://hdl.handle.net/10906/78520 http://dx.doi.org/10.1097/RHU.0000000000000098 |
| Access Level: | acceso abierto |
| Palabra clave: | Arteritis de Takayasu Tratamiento Ciencias socio biomédicas Biomedical sciences Medicina Interleukin-6 Reumatología |
| Sumario: | Purpose: The aim of this study was to describe the efficacy and safety of anti–interleukin 6 receptor antibody (tocilizumab [TCZ]) in patients with severe or refractory Takayasu arteritis (TA). Methods: We describe 8 Colombian patients with severe and/or refractory TA treated with TCZ during a period of at least 9 months. Clinical, radiological, biological, and associated treatments were evaluated before, during, and after TCZ infusions. Results: The median age at evaluation was 31 years (12–43 years). All patients were female and experienced clinical and biological improvement, in addition to a corticosteroid-sparing effect from a median dose of 50 mg/d at baseline (30–60 mg/d) to 6.25 mg/d (2.5–10 mg/d) at 9 months. In 4 cases, in which imaging studies were available, an improvement was observed. |
|---|